R. Schwendener
Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice
Rentsch K, Horber D, Schwendener R, Wunderli-Allenspach H, Haenseler E. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer 1997; 75:986-992.
Jan 1, 1997Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice
Jan 1, 1997Br J Cancer 1997; 75:986-992
Rentsch K.M., Horber Daniel, Schwendener R., Wunderli-Allenspach H., Haenseler E.
Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)
Schwendener R, Horber D, Odermatt B, Schott H. Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C). J Cancer Res Clin Oncol 1996; 122:102-108.
Jan 1, 1996Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)
Jan 1, 1996J Cancer Res Clin Oncol 1996; 122:102-108
Schwendener R., Horber Daniel, Odermatt B., Schott H.
Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Horber D, von Ballmoos P, Schott H, Schwendener R. Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer 1995; 72:1067-1073.
Nov 1, 1995Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Nov 1, 1995Br J Cancer 1995; 72:1067-1073
Horber Daniel, von Ballmoos P., Schott H., Schwendener R.
Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes
Horber D, Ottiger C, Schott H, Schwendener R. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 1995; 47:282-288.
Apr 12, 1995Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes
Apr 12, 1995J Pharm Pharmacol 1995; 47:282-288
Horber Daniel, Ottiger C., Schott H., Schwendener R.
Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Horber D, Schott H, Schwendener R. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer 1995; 71:957-962.
Jan 1, 1995Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Jan 1, 1995Br J Cancer 1995; 71:957-962
Horber Daniel, Schott H., Schwendener R.
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937
Horber D, Schott H, Schwendener R. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 1995; 36:483-492.
Jan 1, 1995Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937
Jan 1, 1995Cancer Chemother Pharmacol 1995; 36:483-492
Horber Daniel, Schott H., Schwendener R.
Monograph: Alkasar-18, 1-(beta-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC
Schwendener R, Horber D, Ottiger C, Rentsch K, Fiebig H, Schott H. Monograph: Alkasar-18, 1-(beta-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC. Drugs of the Future 1995; 20:11-15.
Jan 1, 1995Monograph: Alkasar-18, 1-(beta-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC
Jan 1, 1995Drugs of the Future 1995; 20:11-15
Schwendener R., Horber Daniel, Ottiger C., Rentsch K.M., Fiebig H.H., Schott H.
Preclinical properties of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabino-furanosylcytosine in liposomal preparations
Schwendener R, Horber D, Ottiger C, Schott H. Preclinical properties of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabino-furanosylcytosine in liposomal preparations. J Liposome Res 1995; 5:27-47.
Jan 1, 1995Preclinical properties of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabino-furanosylcytosine in liposomal preparations
Jan 1, 1995J Liposome Res 1995; 5:27-47
Schwendener R., Horber Daniel, Ottiger C., Schott H.
Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer
Pestalozzi B, Vass A, Adam H, Horber D, Schwendener R, Sauter C. Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Eur J Cancer 1995; 31A:1024.
Jan 1, 1995Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer
Jan 1, 1995Eur J Cancer 1995; 31A:1024
Pestalozzi B., Vass A., Adam H., Horber Daniel, Schwendener R., Sauter C.
New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens
Schwendener R, Gowland P, Horber D, Zahner R, Schertler A, Schott H. New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Res 1994; 24:79-93.
May 1, 1994New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens
May 1, 1994Antiviral Res 1994; 24:79-93
Schwendener R., Gowland P., Horber Daniel, Zahner R., Schertler A., Schott H.
Preclinical and clinical experience with liposome encapsulated mitoxantrone
Schwendener R, Horber D, Rentsch K, Haenseler E, Pestalozzi B, Sauter C. Preclinical and clinical experience with liposome encapsulated mitoxantrone. J Liposome Res 1994; 4:605-639.
Jan 1, 1994Preclinical and clinical experience with liposome encapsulated mitoxantrone
Jan 1, 1994J Liposome Res 1994; 4:605-639
Schwendener R., Horber Daniel, Rentsch K.M., Haenseler E., Pestalozzi B., Sauter C.
Synthesis, and some properties of amphiphilic dinucleoside phosphate derivatives of 3'-azido-2',3'-dideoxythymidine (AZT)
Schott H, Horber D, Zahner R, Gowland P, Schwendener R. Synthesis, and some properties of amphiphilic dinucleoside phosphate derivatives of 3'-azido-2',3'-dideoxythymidine (AZT). Antivir Chem Chemother 1994; 5:387-394.
Jan 1, 1994Synthesis, and some properties of amphiphilic dinucleoside phosphate derivatives of 3'-azido-2',3'-dideoxythymidine (AZT)
Jan 1, 1994Antivir Chem Chemother 1994; 5:387-394
Schott H., Horber Daniel, Zahner R., Gowland P., Schwendener R.